*ST百花(600721.SH)2019年度預盈1400萬元到2100萬元
格隆匯1月22日丨*ST百花(600721.SH)公佈,預計2019年度實現歸屬於上市公司股東的淨利潤將出現盈利,實現歸屬於上市公司股東的淨利潤1400萬元到2100萬元。
預計歸屬於上市公司股東的扣除非經常性損益後的淨利潤為200萬元到900萬元。
公司較上年同期相比,主營業務醫藥研發業減少了臨牀批件的銷售,雖然經營利潤有一定的下滑,但仍繼續保持盈利水平。
百花村於2016年完成重大資產重組,收購華威醫藥,合併報表形成商譽17.04億元,2017年度、2018年度累計計提商譽減值15.31億,2018年末商譽1.73億元。目前南京華威公司經營穩定,公司價值穩步增長,商譽減值預計計提在其餘額的0-25%左右(以最終評估報告為準)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.